August 20, 2024Open Access

Figures S1-S9, Tables S1-S5, Appendices 2-4 Data Supplementary1 from Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Materials for Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Honma et al. (Tue,) studied this question.

synapsesocial.com/papers/68e5bb1eb6db643587552ddd https://doi.org/https://doi.org/10.1158/1078-0432.26790291

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The burden of rare cancer in Japan: Application of the RARECARE definition2014 · 76 citations
2Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression2020 · 76 citations
3Introduction to Meta‐Analysis2009 · 13,145 citations
4Incidence of Carcinoma of the Major Salivary Glands According to the WHO Classification, 1992 to 2006: A Population-Based Study in the United States2009 · 291 citations
5Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification2017 · 114 citations

Demander à l'IA

Bookmark

View Full Paper